StackLeaf
Stock · NSE

AUROPHARMA

1,622.10 41.30 (-2.48%)
Last 2 days · 15m candles25/8/2026, 00:35:38
Open: 1,663.70High: 1,665.60Low: 1,622.10Prev: 1,663.40
Positive
10
Neutral
19
Negative
1

News mentioning AUROPHARMA

Sentiment: +30%← All news
VERIFIEDMint Markets·33d★ ON YOUR LIST
Lupin, Sun Pharma to Cipla: Pharma stocks decline after Trump’s tariffs plan on generic medicines import
AI summary· NEGATIVE
  • ·Several Indian pharmaceutical companies experienced a decline in their stock prices.
  • ·Aurobindo Pharma, Ajanta Pharma, Lupin, Gland Pharma, and Zydus Lifesciences were among the top decliners.
  • ·The decline occurred following a plan by Donald Trump regarding tariffs on generic medicine imports.
VERIFIEDMint Markets·54d★ ON YOUR LIST
Aurobindo Pharma’s investors await next leg of growth
AI summary· NEUTRAL
  • ·Aurobindo Pharma's growth is expected to be supported by the Pen-G project ramp-up.
  • ·Integration of Lannett and new US product launches are anticipated to aid growth.
  • ·Expansion in Europe and contributions from higher-margin businesses are also expected to drive growth.
VERIFIEDEconomic Times News·56d★ ON YOUR LIST
Nifty has more room to run; stay selective: Analysts
AI summary· NEUTRAL
  • ·Nifty is targeting the 24,300-25,000 zone amidst market volatility.
  • ·Analysts suggest selective trading and strategies like a moderately bullish Call Spread.
  • ·Recommended stocks include TVS Motor, Samvardhana Motherson International, Oberoi Realty, Aurobindo Pharma, Vijaya Diagnostic Centre, and Mahindra & Mahindra Financial Services.
VERIFIEDET Finance·63d★ ON YOUR LIST
Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett Company
AI summary· POSITIVE
  • ·Aurobindo Pharma's US subsidiary received Federal Trade Commission approval for the $250 million acquisition of Lannett Company.
  • ·The acquisition is anticipated to be finalized by June 2026.
  • ·The deal is expected to enhance Aurobindo's complex generics and controlled substances offerings and immediately increase earnings per share.